Impel NeuroPharma Announces Last Patient Enrolled In Phase 3 Trial Evaluating INP104 For The Treatment Of Acute Migraine

Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) disorders with high unmet medical needs, announced the last patient has been enrolled in “STOP-301” (Safety and Tolerability of POD-DHE), the Company’s pivotal open-label Phase 3, multi-use, long-term safety and tolerability of INP104 for the treatment of acute migraine.

STOP-301 is evaluating the safety of long-term, intermittent use of INP104 for 24-week and 52-week data points and will also collect efficacy data of INP104 as assessed by change from baseline in migraine measures during the course of the study. Following a four-week screening period, a total of 360 patients have been enrolled in the study. A subset of 73 patients will continue into a 28-week treatment extension period and a two-week post-treatment follow-up period. There are currently 36 sites in the United States with patients enrolled in the study.

“INP104 has the potential to provide IV-like dihydroergotamine (DHE) effects in the home with rapid onset and long-lasting benefits because it reaches the vascular rich upper nasal cavity, an emerging new area of the body for drug administration,” said Stephen B. Shrewsbury, M.D., Chief Medical Officer of Impel NeuroPharma. “Although the use of DHE has been limited due to route of administration, it remains a trusted treatment for acute migraine in headache clinics. Importantly, because INP104 is designed to provide consistent delivery of DHE, it can be used anytime and anywhere by the patient. We look forward to sharing the top-line results of STOP-301 in early 2020.”

INP104 is a DHE product dosed via Impel’s proprietary Precision Olfactory Delivery, or POD®, nasal drug delivery device. DHE was first introduced in 1946, and over time, has demonstrated to be a safe and effective treatment for acute migraine, with a consistent response to intravenous administration. Based on discussions with the FDA, this pivotal Phase 3 safety study for INP104 and a previously completed comparative bioavailability trial between INP104, IV DHE and Migranal are the final clinical requirements to file a New Drug Application (NDA) for INP104. Pending complete review of the clinical study data, the Company expects to be in a position to file a NDA in the second half of 2020.